Danish CNS specialist Lundbeck (LUND: CO) has entered into an agreement with Israel-based biotech company ImmunoBrain Checkpoint (IBC) for the rights to the latter's groundbreaking research in the treatment of Alzheimer's disease.
The research focuses on modifying antibodies currently used in cancer treatment for use in treating the debilitating brain disease from which 48 million patients are estimated to suffer, a number expected to rapidly increase in the future.
"IBC has a unique and innovative approach to this highly complex disease and the data generated until now are highly promising. We are delighted to take part in this exciting work as part of our strategy of in-licensing research projects to supplement our own research activities," says Jacob Tolstrup, executive vice president for corporate functions, including business development, at Lundbeck.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze